{"id":60437,"date":"2024-02-28T06:48:51","date_gmt":"2024-02-28T06:48:51","guid":{"rendered":"https:\/\/medsname.com\/rioci-1\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"rioci-1","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/rioci-1\/","title":{"rendered":"Rioci 1"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">\u26a1 Rychl\u00e1 odpov\u011b\u010f \u2014 Co je Rioci 1?<\/h3>\n<p style=\"margin:0;\"><strong>Rioci 1<\/strong> jsou tablety riociguatu 1 mg od v\u00fdrobce certifikovan\u00e9ho WHO-GMP \u2014 stimul\u00e1tor solubiln\u00ed guanyl\u00e1tcykl\u00e1zy (sGC) ur\u010den\u00fd pro <strong>plicn\u00ed arteri\u00e1ln\u00ed hypertenzi (PAH)<\/strong>. PAH je specifick\u00e9, progresivn\u00ed a vz\u00e1cn\u00e9 onemocn\u011bn\u00ed \u2014 <strong>nejde o tot\u00e9\u017e co syst\u00e9mov\u00e1 hypertenze<\/strong>. Zvy\u0161uje tlak v plicn\u00edch tepn\u00e1ch, nikoli v syst\u00e9mov\u00fdch tepn\u00e1ch, a vy\u017eaduje specializovanou terapii pod veden\u00edm odborn\u00edk\u016f na akreditovan\u00e9m centru pro plicn\u00ed arteri\u00e1ln\u00ed hypertenzi (PAH). Riociguat byl uveden na trh spole\u010dnost\u00ed Bayer v roce 2013 jako <strong>Adempas<\/strong> \u2014 prvn\u00ed stimul\u00e1tor sGC schv\u00e1len\u00fd pro lidsk\u00e9 pou\u017eit\u00ed. Schv\u00e1len FDA pro dv\u011b specifick\u00e9 formy plicn\u00ed hypertenze: plicn\u00ed arteri\u00e1ln\u00ed hypertenzi (PAH, WHO skupina 1) a chronickou tromboembolickou plicn\u00ed hypertenzi (CTEPH, WHO skupina 4) \u2014 jedin\u00e9 peror\u00e1ln\u00ed l\u00e9\u010divo schv\u00e1len\u00e9 pro neoperovatelnou CTEPH. P\u0159\u00edmo aktivuje solubiln\u00ed guanyl\u00e1tcykl\u00e1zu (receptor NO) v hladk\u00e9m svalstvu plicn\u00edch tepen, zvy\u0161uje hladinu cGMP a zp\u016fsobuje plicn\u00ed vazodilataci. Na rozd\u00edl od inhibitor\u016f PDE5 riociguat stimuluje sGC i p\u0159i absenci NO, co\u017e zaji\u0161\u0165uje \u00fa\u010dinnost v c\u00e9vn\u00edch \u0159e\u010di\u0161t\u00edch s nedostatkem NO, typick\u00fdch pro PAH a CTEPH. D\u00e1vkov\u00e1n\u00ed: Za\u010dn\u011bte s 1 mg t\u0159ikr\u00e1t denn\u011b (v 8hodinov\u00fdch intervalech); d\u00e1vku upravujte ka\u017ed\u00e9 2 t\u00fddny o 0,5 mg na z\u00e1klad\u011b systolick\u00e9ho TK (mus\u00ed z\u016fstat &gt;95 mmHg) a p\u0159\u00edznak\u016f. C\u00edlov\u00e1 d\u00e1vka je 2,5 mg t\u0159ikr\u00e1t denn\u011b. L\u00e9\u010dba PAH je obvykle kombinovan\u00e1 terapie zah\u00e1jen\u00e1 a monitorovan\u00e1 na specializovan\u00e9m centru; nejde o onemocn\u011bn\u00ed, kter\u00e9 lze l\u00e9\u010dit sv\u00e9pomoc\u00ed.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Co z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch <a href=\"https:\/\/medsbase.com\/cs\/reviews\/\">recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed <a href=\"https:\/\/medsbase.com\/cs\/medsbase-re-shipment-assurance-policy\/\"><strong>Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n<h3>Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n<p>Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n<h2 class=\"wp-block-heading\">Co je Rioci 1?<\/h2>\n<p>Rioci 1 jsou tablety riociguatu 1 mg od v\u00fdrobce certifikovan\u00e9ho WHO-GMP, dod\u00e1van\u00e9 v balen\u00ed po 10\u2013180 tablet\u00e1ch. Riociguat byl uveden na trh spole\u010dnost\u00ed Bayer v roce 2013 jako <strong>Adempas<\/strong> \u2014 prvn\u00ed stimul\u00e1tor sGC schv\u00e1len\u00fd pro lidsk\u00e9 pou\u017eit\u00ed. Schv\u00e1len FDA pro dv\u011b specifick\u00e9 formy plicn\u00ed hypertenze: plicn\u00ed arteri\u00e1ln\u00ed hypertenzi (PAH, WHO skupina 1) a chronickou tromboembolickou plicn\u00ed hypertenzi (CTEPH, WHO skupina 4) \u2014 jedin\u00e9 peror\u00e1ln\u00ed l\u00e9\u010divo schv\u00e1len\u00e9 pro neoperovatelnou CTEPH.<\/p>\n<p><strong>Plicn\u00ed arteri\u00e1ln\u00ed hypertenze (PAH) nen\u00ed syst\u00e9mov\u00e1 hypertenze.<\/strong> PAH se konkr\u00e9tn\u011b t\u00fdk\u00e1 zv\u00fd\u0161en\u00e9ho tlaku v plicn\u00edm arteri\u00e1ln\u00edm ob\u011bhu (\u226520 mmHg st\u0159edn\u00ed tlak v plicnici s plicn\u00ed vaskul\u00e1rn\u00ed rezistenc\u00ed \u22652 Woodovy jednotky dle sm\u011brnic ESC\/ERS z roku 2022). Je to vz\u00e1cn\u00e9 onemocn\u011bn\u00ed (odhadovan\u00fd v\u00fdskyt 15\u201350 na milion dosp\u011bl\u00fdch), progresivn\u00ed a bez l\u00e9\u010dby m\u00e1 \u0161patnou progn\u00f3zu (historick\u00e9 5let\u00e9 p\u0159e\u017eit\u00ed \u223c30 %). Modern\u00ed terapie c\u00edlen\u00e1 na PAH zlep\u0161ila 5let\u00e9 p\u0159e\u017eit\u00ed na 60\u201370 % ve specializovan\u00fdch centrech.<\/p>\n<p>Kandid\u00e1ti pro Rioci 1 byli diagnostikov\u00e1ni na specializovan\u00e9m centru pro PAH pomoc\u00ed katetrizace prav\u00e9ho srdce, s p\u0159\u00edznaky funk\u010dn\u00ed t\u0159\u00eddy WHO\/NYHA II\u2013IV a potvrzenou PAH (WHO skupina 1) nebo \u2014 v p\u0159\u00edpad\u011b riociguatu \u2014 neoperovatelnou nebo perzistuj\u00edc\u00ed CTEPH (WHO skupina 4). Tento l\u00e9k nen\u00ed ur\u010den pro b\u011b\u017enou hypertenzi ani pro samostatn\u011b zah\u00e1jenou terapii.<\/p>\n<h2 class=\"wp-block-heading\">Jak riociguat funguje<\/h2>\n<p>P\u0159\u00edmo aktivuje solubiln\u00ed guanyl\u00e1tcykl\u00e1zu (receptor NO) v hladk\u00e9m svalstvu plicn\u00edch tepen, zvy\u0161uje hladinu cGMP a zp\u016fsobuje plicn\u00ed vazodilataci. Na rozd\u00edl od inhibitor\u016f PDE5 riociguat stimuluje sGC i p\u0159i absenci NO, co\u017e zaji\u0161\u0165uje \u00fa\u010dinnost v c\u00e9vn\u00edch \u0159e\u010di\u0161t\u00edch s nedostatkem NO, typick\u00fdch pro PAH a CTEPH.<\/p>\n<h2 class=\"wp-block-heading\">D\u016fkazy<\/h2>\n<p><strong>PATENT-1 (2013)<\/strong> \u2014 riociguat u 443 pacient\u016f s PAH; vzd\u00e1lenost u\u0161lou za 6 minut se zlep\u0161ila o 30 m oproti placebu, s lep\u0161\u00ed funk\u010dn\u00ed t\u0159\u00eddou WHO a odd\u00e1len\u00fdm klinick\u00fdm zhor\u0161en\u00edm. <strong>CHEST-1 (2013)<\/strong> \u2014 riociguat u 261 pacient\u016f s neoperovatelnou nebo perzistuj\u00edc\u00ed CTEPH; vzd\u00e1lenost u\u0161lou za 6 minut se zlep\u0161ila o 46 m oproti placebu.<\/p>\n<h2 class=\"wp-block-heading\">D\u00e1vkov\u00e1n\u00ed a monitorov\u00e1n\u00ed<\/h2>\n<p><strong>D\u00e1vkov\u00e1n\u00ed:<\/strong> Za\u010dn\u011bte s 1 mg t\u0159ikr\u00e1t denn\u011b (v 8hodinov\u00fdch intervalech); titrujte ka\u017ed\u00e9 2 t\u00fddny po 0,5 mg na z\u00e1klad\u011b systolick\u00e9ho TK (mus\u00ed z\u016fstat &gt;95 mmHg) a p\u0159\u00edznak\u016f. C\u00edlov\u00e1 d\u00e1vka je 2,5 mg t\u0159ikr\u00e1t denn\u011b.<\/p>\n<p><strong>Monitorov\u00e1n\u00ed:<\/strong> P\u0159i zah\u00e1jen\u00ed l\u00e9\u010dby a ka\u017ed\u00e9 3\u20136 m\u011bs\u00edce pot\u00e9 \u2014 funk\u010dn\u00ed t\u0159\u00edda WHO, 6minutov\u00e1 vzd\u00e1lenost ch\u016fze, NT-proBNP, opakovan\u00e1 echokardiografie a (v del\u0161\u00edch intervalech) pravostrann\u00e1 katetrizace srdce. V\u0161e prov\u00e1d\u011bno ve specializovan\u00e9m centru pro PAH.<\/p>\n<p><strong>Monitorov\u00e1n\u00ed TK:<\/strong> systolick\u00fd TK mus\u00ed z\u016fstat &gt;95 mmHg; zv\u00fd\u0161en\u00ed d\u00e1vky se pozastav\u00ed nebo sn\u00ed\u017e\u00ed p\u0159i symptomatick\u00e9 hypotenzi.<\/p>\n<h2 class=\"wp-block-heading\">Vedlej\u0161\u00ed \u00fa\u010dinky<\/h2>\n<ul>\n<li><strong>Hypotenze<\/strong> \u2014 limituj\u00edc\u00ed d\u00e1vka; titrujte pomalu.<\/li>\n<li><strong>Hemopt\u00fdza<\/strong> \u2014 zv\u00fd\u0161en\u00e9 riziko, zejm\u00e9na u CTEPH.<\/li>\n<li>Synkopa<\/li>\n<li>Bolest hlavy, z\u00e1vrat\u011b<\/li>\n<li>Perifern\u00ed ed\u00e9m<\/li>\n<li>An\u00e9mie<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Kontraindikace<\/h2>\n<ul>\n<li><strong>Sou\u010dasn\u00e9 pod\u00e1v\u00e1n\u00ed inhibitor\u016f PDE5<\/strong> (sildenafil, tadalafil) \u2014 aditivn\u00ed zv\u00fd\u0161en\u00ed cGMP, t\u011b\u017ek\u00e1 hypotenze. Kontraindikovan\u00e1 kombinace.<\/li>\n<li><strong>Sou\u010dasn\u00e9 pod\u00e1v\u00e1n\u00ed nitr\u00e1t\u016f nebo donor\u016f NO<\/strong> \u2014 stejn\u00fd d\u016fvod; kontraindikov\u00e1no.<\/li>\n<li>T\u011bhotenstv\u00ed \u2014 embryofet\u00e1ln\u00ed toxicita (v USA program REMS: \u017eeny mus\u00ed pou\u017e\u00edvat antikoncepci a prov\u00e1d\u011bt m\u011bs\u00ed\u010dn\u00ed t\u011bhotensk\u00e9 testy)<\/li>\n<\/ul>\n<h2 id=\"faqs\">\u010casto kladen\u00e9 dotazy<\/h2>\n<h3 class=\"wp-block-heading\">Je plicn\u00ed arteri\u00e1ln\u00ed hypertenze tot\u00e9\u017e co \u201cvysok\u00fd krevn\u00ed tlak\u201d?<\/h3>\n<p>Ne. Syst\u00e9mov\u00e1 hypertenze je zv\u00fd\u0161en\u00fd tlak v syst\u00e9mov\u00e9m ob\u011bhu a je velmi \u010dast\u00e1; PAH je zv\u00fd\u0161en\u00fd tlak specificky v plicn\u00edm ob\u011bhu a je vz\u00e1cn\u00e1. Maj\u00ed r\u016fzn\u00e9 p\u0159\u00ed\u010diny, r\u016fzn\u00e9 specialisty (PAH je typicky v p\u00e9\u010di pneumologick\u00fdch\/kardiologick\u00fdch t\u00fdm\u016f ve specializovan\u00fdch centrech) a velmi odli\u0161nou l\u00e9\u010dbu. L\u00e9k, kter\u00fd sni\u017euje syst\u00e9mov\u00fd TK (ACEi, ARB, CCB, thiazid), obvykle m\u00e1 mal\u00fd \u00fa\u010dinek na PAH.<\/p>\n<h3 class=\"wp-block-heading\">Pro\u010d p\u0159\u00edpravek Rioci 1 vy\u017eaduje odborn\u00fd dohled?<\/h3>\n<p>PAH je onemocn\u011bn\u00ed vy\u017eaduj\u00edc\u00ed specializovanou p\u00e9\u010di s registrov\u00fdm modelem sledov\u00e1n\u00ed ve v\u011bt\u0161in\u011b zem\u00ed. L\u00e9ky jsou drah\u00e9, maj\u00ed specifick\u00e9 ne\u017e\u00e1douc\u00ed \u00fa\u010dinky (zejm\u00e9na hepatotoxicitu u ERA a hypotenzi u stimul\u00e1tor\u016f sGC) a d\u00e1vkov\u00e1n\u00ed se upravuje na z\u00e1klad\u011b pravideln\u00fdch vy\u0161et\u0159en\u00ed (6minutov\u00fd test ch\u016fze, funk\u010dn\u00ed t\u0159\u00edda, NT-proBNP, echokardiografie). Samol\u00e9\u010dba mimo indikaci nese vysok\u00e9 riziko klinick\u00e9ho zhor\u0161en\u00ed.<\/p>\n<h3 class=\"wp-block-heading\">Mohu u\u017e\u00edvat p\u0159\u00edpravek Rioci 1 s l\u00e9ky na erektiln\u00ed dysfunkci?<\/h3>\n<p><strong>Ne \u2014 absolutn\u011b kontraindikov\u00e1no.<\/strong> Inhibitory PDE5 (sildenafil, tadalafil, vardenafil) v kombinaci s riociguatem zp\u016fsobuj\u00ed z\u00e1va\u017enou aditivn\u00ed hypotenzi. Pokud pot\u0159ebujete terapii ED, proberte alternativy se sv\u00fdm t\u00fdmem pro plicn\u00ed arteri\u00e1ln\u00ed hypertenzi (PAH); n\u011bkter\u00e9 re\u017eimy PAH pou\u017e\u00edvaj\u00ed inhibitory PDE5 m\u00edsto riociguatu jako plicn\u00ed vazodilat\u00e1tor.<\/p>\n<h3 class=\"wp-block-heading\">Mohu u\u017e\u00edvat p\u0159\u00edpravek Rioci 1 v t\u011bhotenstv\u00ed?<\/h3>\n<p><strong>Ne.<\/strong> Embryofet\u00e1ln\u00ed toxicita byla dokumentov\u00e1na ve studi\u00edch na zv\u00ed\u0159atech; vy\u017eaduje se t\u011bhotensk\u00fd test a antikoncepce.<\/p>\n<h3 class=\"wp-block-heading\">Kde lze koupit p\u0159\u00edpravek Rioci 1 online?<\/h3>\n<p>P\u0159\u00edpravek Rioci 1 (riociguat 1 mg, 10\u2013180 tablet) m\u016f\u017eete koupit na MedsBase s diskr\u00e9tn\u00edm balen\u00edm a celosv\u011btovou dopravou.<\/p>\n<h2 class=\"wp-block-heading\">Souvisej\u00edc\u00ed kardiovaskul\u00e1rn\u00ed l\u00e9ky<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/cs\/cardace\/\">Cardace \u2014 Ramipril (ACE inhibitor)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/ecopril\/\">Ecopril \u2014 Clopidogrel 75 mg (antiagregancium)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/ecosprin\/\">Ecosprin \u2014 Aspirin 75\/150 mg (antiagrega\u010dn\u00ed)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/lonitab\/\">Lonitab \u2014 Minoxidil 5 mg (or\u00e1ln\u00ed vazodilat\u00e1tor)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/waf-5\/\">Waf-5 \u2014 Warfarin 5 mg (VKA)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/xarelto-20\/\">Xarelto 20 \u2014 Rivaroxaban 20 mg (DOAC)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/high-blood-pressure-medication\/\"><strong>Prohl\u00e9dnout v\u0161echny l\u00e9ky na vysok\u00fd krevn\u00ed tlak<\/strong><\/a><\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:16px 20px;margin:24px 0;border-radius:4px;\"><strong>\u2695 L\u00e9ka\u0159sk\u00e9 upozorn\u011bn\u00ed.<\/strong> Tato str\u00e1nka slou\u017e\u00ed pouze pro informa\u010dn\u00ed \u00fa\u010dely a nenahrazuje l\u00e9ka\u0159skou p\u00e9\u010di kvalifikovan\u00e9ho zdravotnick\u00e9ho pracovn\u00edka. Hypertenze, srde\u010dn\u00ed selh\u00e1n\u00ed a arytmie vy\u017eaduj\u00ed diagn\u00f3zu, monitorov\u00e1n\u00ed a individu\u00e1ln\u00ed d\u00e1vkov\u00e1n\u00ed l\u00e9ka\u0159em \u2014 v\u017edy u\u017e\u00edvejte betablok\u00e1tory pod l\u00e9ka\u0159sk\u00fdm dohledem.<\/div>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Souvisej\u00edc\u00ed alternativy<\/h3>\n<p>Dal\u0161\u00ed produkty v <strong>Chronick\u00e1 onemocn\u011bn\u00ed<\/strong> kter\u00e9 z\u00e1kazn\u00edci tak\u00e9 prohl\u00ed\u017eej\u00ed:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/cs\/seretra\/\">Seretra<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/proclid-5\/\">Proclid 5<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/tacroz-forte-ointment\/\">Tacroz Forte Ointment<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/syndopa\/\">Syndopa<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/caditam\/\">Caditam<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>Rioci 1 jsou tablety riociguatu 1 mg \u2014 prvn\u00ed stimul\u00e1tor solubiln\u00ed guanyl\u00e1tcykl\u00e1zy (sGC), p\u016fvodn\u011b Bayer Adempas (2013). Schv\u00e1len pro plicn\u00ed arteri\u00e1ln\u00ed hypertenzi (PAH, WHO skupina 1) a jedin\u00fd peror\u00e1ln\u00ed l\u00e9k pro neoperovatelnou chronickou tromboembolickou plicn\u00ed hypertenzi (CTEPH, WHO skupina 4). D\u016fkazy z PATENT-1 a CHEST-1 studi\u00ed. Onemocn\u011bn\u00ed vy\u017eaduj\u00edc\u00ed specializovanou p\u00e9\u010di \u2014 ne b\u011b\u017enou hypertenzi. Kontraindikov\u00e1n s inhibitory PDE5 a nitr\u00e1ty.<\/p>","protected":false},"featured_media":60438,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3260,3356],"product_tag":[4861,4862],"class_list":{"0":"post-60437","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-heart-blood-pressure","9":"product_cat-high-blood-pressure-medication","10":"product_tag-rioci","11":"product_tag-riociguat","13":"first","14":"instock","15":"shipping-taxable","16":"purchasable","17":"product-type-variable","18":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product\/60437","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/comments?post=60437"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media\/60438"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media?parent=60437"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_brand?post=60437"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat?post=60437"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_tag?post=60437"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}